Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Nuvectis Pharma, Inc. NVCT NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
46/100
3/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$10.00
+14.5%

Nuvectis Pharma, Inc. (NVCT) is a Biotechnology company in the Healthcare sector, currently trading at $8.73. It has a SharesGrow Score of 44/100, indicating a mixed investment profile with 3 out of 7 criteria passed.

Analyst consensus target is NVCT = $10 (+14.5% upside).

Valuation: NVCT trades at a trailing Price-to-Earnings (P/E) of -6.6 (S&P 500 average ~25).

Net income is $26M (loss), growing at -14.3%/yr. Net profit margin is 0% (thin). Gross margin is -12808.7% (+0 pp trend).

Balance sheet: total debt is $0 against $18M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 2.38 (strong liquidity). Debt-to-assets is 0%. Total assets: $32M.

Analyst outlook: 2 / 2 analysts rate NVCT as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 60/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 11/100 (Fail), Future 88/100 (Pass), Income ?/100 (Fail).

$10.00
▲ 14.55% Upside
Average Price Target
The 12-month price target for Nuvectis Pharma, Inc. is $10.00.

NVCT SharesGrow Score Overview

55/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 60/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 11/100
Gross margin is + market cap
FUTURE 88/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — NVCT

✓
VALUE Pass
60/100
NVCT trades at a trailing Price-to-Earnings (P/E) of -6.6 (S&P 500 average ~25). Forward PEG -1.67 — Peter Lynch undervalued (≤1.0). Analyst consensus target is $10, implying +14.5% from the current price $9. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
NVCT: -100%/yr revenue is, -14.3%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet NVCT: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 2.38 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
11/100
NVCT: Gross margin is -12808.7% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 11/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
88/100
Analyst outlook: 2 / 2 analysts rate NVCT as buy (100%). Analyst consensus target is $10 (+14.5% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range5.55-11.52
Volume43.83K
Avg Volume (30D)57.91K
Market Cap$231.27M
Beta (1Y)-0.21
Share Statistics
EPS (TTM)-1.32
Shares Outstanding$21.81M
IPO Date2022-02-04
Employees13
CEORon Bentsur
Financial Highlights & Ratios
EBITDA$-27.57M
Net Income$-26.44M
Operating Income$-27.57M
Total Cash$31.63M
Net Debt$-31.63M
Total Assets$31.71M
Price / Earnings (P/E)-6.6
Analyst Forecast
1Y Price Target$10.00
Target High$10.00
Target Low$10.00
Upside+14.5%
Rating ConsensusBuy
Analysts Covering2
Buy 100% Hold 0% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS67080T1088

Price Chart

Track all markets on TradingView
NVCT
Nuvectis Pharma, Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Biotechnology
5.55 52WK RANGE 11.52

People Also View

CNTA
CNTA
Centessa Pharmaceuticals plc
$39.59
+0.05%
 CELC
CELC
Celcuity Inc.
$120.85
+0.37%
 NAMS
NAMS
NewAmsterdam Pharma Company N.V.
$34.44
-4.99%
 EWTX
EWTX
Edgewise Therapeutics, Inc.
$33.16
-2.01%
 OLMA
OLMA
Olema Pharmaceuticals, Inc.
$16.30
+2.32%
 GLUE
GLUE
Monte Rosa Therapeutics, Inc.
$17.50
-0.28%
 CGEM
CGEM
Cullinan Oncology, Inc.
$14.35
+0.70%
 CMPX
CMPX
Compass Therapeutics, Inc.
$5.44
+4.62%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message